The global economic impact of diabetes has turned the continuous glucose monitoring system market size into a multi-billion dollar juggernaut. Valued at nearly USD 12 billion in 2025, the market is a cornerstone of the medical device industry. This scale is driven by the recurring revenue model of sensors, where a single patient can generate thousands of dollars in annual sales. This "subscription-like" financial structure makes the sector highly attractive to investors and has led to a surge in venture capital for startups working on non-invasive laser or optical sensing technologies.

Economic analysts also highlight the "indirect" value of the market—specifically the savings for healthcare systems. By reducing hospitalizations due to severe hypo- or hyperglycemia, CGM systems save insurers billions in emergency room costs. This "cost-offset" argument is the primary reason why more government health programs are moving to fully reimburse the technology for Type 2 patients. As the market reaches economies of scale, the cost of production is expected to drop, potentially allowing for a "low-cost" tier of devices tailored for developing nations and underserved communities.